BR112012005343A2 - sulfonamidas como inibidores de proteínas da família bcl-2 para o tratamento de câncer - Google Patents

sulfonamidas como inibidores de proteínas da família bcl-2 para o tratamento de câncer

Info

Publication number
BR112012005343A2
BR112012005343A2 BR112012005343A BR112012005343A BR112012005343A2 BR 112012005343 A2 BR112012005343 A2 BR 112012005343A2 BR 112012005343 A BR112012005343 A BR 112012005343A BR 112012005343 A BR112012005343 A BR 112012005343A BR 112012005343 A2 BR112012005343 A2 BR 112012005343A2
Authority
BR
Brazil
Prior art keywords
sulfonamides
bcl
cancer treatment
family protein
protein inhibitors
Prior art date
Application number
BR112012005343A
Other languages
English (en)
Portuguese (pt)
Inventor
Bakary-Barry Toure
Karen Miller-Moslin
Michael Scott Visser
Naeem Yusuff
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112012005343A2 publication Critical patent/BR112012005343A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
BR112012005343A 2009-09-10 2010-09-08 sulfonamidas como inibidores de proteínas da família bcl-2 para o tratamento de câncer BR112012005343A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24125109P 2009-09-10 2009-09-10
PCT/EP2010/063169 WO2011029842A1 (en) 2009-09-10 2010-09-08 Sulfonamides as inhibitors of bcl-2 family proteins for the treatment of cancer

Publications (1)

Publication Number Publication Date
BR112012005343A2 true BR112012005343A2 (pt) 2016-03-22

Family

ID=43016684

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012005343A BR112012005343A2 (pt) 2009-09-10 2010-09-08 sulfonamidas como inibidores de proteínas da família bcl-2 para o tratamento de câncer

Country Status (12)

Country Link
US (1) US8809352B2 (enExample)
EP (1) EP2475661B1 (enExample)
JP (1) JP2013504536A (enExample)
KR (1) KR20120078715A (enExample)
CN (1) CN102498111A (enExample)
AU (1) AU2010294292B2 (enExample)
BR (1) BR112012005343A2 (enExample)
CA (1) CA2772989A1 (enExample)
EA (1) EA020586B1 (enExample)
ES (1) ES2443845T3 (enExample)
MX (1) MX2012003007A (enExample)
WO (1) WO2011029842A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101762724B1 (ko) * 2011-01-25 2017-07-28 더 리젠츠 오브 더 유니버시티 오브 미시건 Bcl-2/bcl-xl 억제제 및 이를 이용한 치료 방법
AU2012355623A1 (en) 2011-12-23 2014-07-17 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
AU2012355613A1 (en) 2011-12-23 2014-07-17 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
LT6064B (lt) 2012-10-15 2014-08-25 Vilniaus Universitetas Fluorinti benzensulfonamidai kaip karboanhidrazės inhibitoriai
ES2670550T3 (es) 2013-10-14 2018-05-30 Eisai R&D Management Co., Ltd. Derivados de quinolina selectivamente sustituidos
KR101823488B1 (ko) 2013-10-14 2018-01-30 에자이 알앤드디 매니지먼트 가부시키가이샤 선택적으로 치환된 퀴놀린 화합물
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
CA2990477A1 (en) * 2015-08-12 2017-02-16 Memorial Sloan-Kettering Cancer Center Phenylsulfonamido-benzofuran derivatives and uses thereof in the treatment of proliferative diseases
AU2017206731A1 (en) * 2016-01-11 2018-08-02 Merrimack Pharmaceuticals, Inc. Inhibiting B-cell lymphoma 2 (Bcl-2) and related proteins
EP3936153B1 (en) 2016-01-11 2024-08-21 Celator Pharmaceuticals, Inc. Inhibiting ataxia telangiectasia and rad3-related protein (atr)
CN112437772B (zh) 2018-04-29 2023-11-21 百济神州有限公司 Bcl-2抑制剂
JP2022522534A (ja) 2019-04-02 2022-04-19 アリゴス セラピューティクス インコーポレイテッド Prmt5を標的にする化合物
WO2021083135A1 (en) 2019-10-28 2021-05-06 Beigene, Ltd. Bcl-2 INHIBITORS
CN116969937B (zh) 2020-04-15 2026-03-24 百济神州(苏州)生物科技有限公司 Bcl-2抑制剂
EP4538273A1 (en) * 2022-06-10 2025-04-16 Hitgen Inc. Compound and use thereof in preparation of bcl-xl inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
ATE372330T1 (de) * 2002-03-21 2007-09-15 Abbott Lab N-sulfonylurea-apoptosis-förderer
US20040157836A1 (en) * 2002-10-08 2004-08-12 Comess Kenneth M. Sulfonamides having antiangiogenic and anticancer activity
CN101039662A (zh) * 2004-08-20 2007-09-19 密执安州立大学董事会 抗-细胞凋亡bcl-2家族成员的小分子抑制剂及其应用
AU2007319209B2 (en) * 2006-11-15 2012-04-19 Genentech, Inc. Arylsulfonamide compounds
FR2912145B1 (fr) * 2007-02-02 2009-03-06 Servier Lab Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
EA020586B1 (ru) 2014-12-30
EP2475661A1 (en) 2012-07-18
ES2443845T3 (es) 2014-02-20
AU2010294292A1 (en) 2012-03-01
JP2013504536A (ja) 2013-02-07
EP2475661B1 (en) 2013-10-23
WO2011029842A1 (en) 2011-03-17
MX2012003007A (es) 2012-04-11
CN102498111A (zh) 2012-06-13
EA201200472A1 (ru) 2012-10-30
US8809352B2 (en) 2014-08-19
US20120165298A1 (en) 2012-06-28
KR20120078715A (ko) 2012-07-10
CA2772989A1 (en) 2011-03-17
AU2010294292B2 (en) 2013-07-18

Similar Documents

Publication Publication Date Title
BRPI1008566A2 (pt) métodos e composições para o diagnóstico e tratamento de câncer
BRPI1007972A2 (pt) composições de combinação e métodos para o tratamento de câncer
PT3483143T (pt) Derivados da piperidinona como inibidores da mdm2 para o tratamento do cancro
BR112012005594A2 (pt) tratamento de câncer
PT2434891T (pt) Métodos para tratamento de cancro e afeções não neoplásicas
BRPI1015215A2 (pt) porções de ligação alvo armadas com amatoxina para o tratamento de câncer
BRPI1013618A2 (pt) pirimidinas substituídas para o tratamento de câncer
BRPI1010874A8 (pt) composição para o tratamento de câncer de próstata
BR112012018947A2 (pt) composição farmacêutica para tratamento e\ou prevenção do cancêr
CO6930321A2 (es) Curación de tejidos
BR112013008738A2 (pt) processos para purificação de proteínas
PT2523661T (pt) Inibidores de nkcc para o tratamento de autismo
BRPI0919238A2 (pt) métodos e composições para o tratamento de câncer
BRPI1009919A2 (pt) combinações de pentamidina para tratamento de câncer.
PT2632452T (pt) Compostos e composições para o tratamento do cancro
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
EP2627333A4 (en) Combination treatment of cancer
BR112012000502A2 (pt) terapia de combinação para o tratamento de diabetes
BR112015006512A2 (pt) composição para tratar tecidos biológicos danificados
PT2427193T (pt) Utilização de inibidores da pde7 para o tratamento de distúrbios do movimento
BRPI1008667A2 (pt) aperfeiçoamento do grampeador cirúrgico acionado
BRPI0922884A2 (pt) compostos para tratamento de câncer
BRPI0909016A2 (pt) anticorpos úteis para o tratamento do câncer
BR112012008959A2 (pt) tratamento de terapia de combinação para infecções virais
BR112012004836A2 (pt) pirazinilpiridinas úteis para o tratamento de doenças proliferativas

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.